{"info": {"address1": "Lilly Corporate Center", "city": "Indianapolis", "state": "IN", "zip": "46285", "country": "United States", "phone": "317 276 2000", "website": "https://www.lilly.com", "industry": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.", "fullTimeEmployees": 39000, "companyOfficers": [{"maxAge": 1, "name": "Mr. David A. Ricks", "age": 54, "title": "Chairman, CEO & Pres", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 4416885, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anat  Ashkenazi", "age": 49, "title": "Exec. VP & CFO", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": 2125270, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Daniel M. Skovronsky M.D., Ph.D.", "age": 48, "title": "Exec. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Laboratories", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": 2716346, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anat  Hakim J.D.", "age": 53, "title": "Exec. VP, Gen. Counsel & Sec.", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 1979674, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrik  Jonsson", "age": 55, "title": "EVP, Chief Customer Officer, Pres of Lilly USA & Lilly Immunology", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": 1673270, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Donald A. Zakrowski", "title": "Chief Accounting Officer & VP of Fin.", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Diogo  Rau", "title": "EVP & Chief Information and Digital Officer", "fiscalYear": 2021, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alonzo  Weems", "age": 51, "title": "EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer", "yearBorn": 1971, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leigh Ann Pusey", "age": 59, "title": "Exec. VP of Corp. Affairs & Communications", "yearBorn": 1963, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric  Dozier", "age": 55, "title": "Exec. VP of HR & Diversity", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 5, "compensationRisk": 2, "shareHolderRightsRisk": 9, "overallRisk": 6, "governanceEpochDate": 1680307200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 372.35, "open": 373.0, "dayLow": 369.66, "dayHigh": 374.26, "regularMarketPreviousClose": 372.35, "regularMarketOpen": 373.0, "regularMarketDayLow": 369.66, "regularMarketDayHigh": 374.26, "dividendRate": 4.52, "dividendYield": 0.0121, "exDividendDate": 1676332800, "payoutRatio": 0.56810004, "fiveYearAvgDividendYield": 1.71, "beta": 0.362975, "trailingPE": 53.610146, "forwardPE": 31.589241, "volume": 1921406, "regularMarketVolume": 1921406, "averageVolume": 3272118, "averageVolume10days": 2624020, "averageDailyVolume10Day": 2624020, "bid": 0.0, "ask": 374.0, "bidSize": 1200, "askSize": 800, "marketCap": 352282673152, "fiftyTwoWeekLow": 276.83, "fiftyTwoWeekHigh": 376.31, "priceToSalesTrailing12Months": 12.342866, "fiftyDayAverage": 337.4432, "twoHundredDayAverage": 337.7635, "trailingAnnualDividendRate": 3.92, "trailingAnnualDividendYield": 0.010527729, "currency": "USD", "enterpriseValue": 352190660608, "profitMargins": 0.2188, "floatShares": 898432505, "sharesOutstanding": 952347008, "sharesShort": 7229324, "sharesShortPriorMonth": 6806393, "sharesShortPreviousMonthDate": 1677542400, "dateShortInterest": 1680220800, "sharesPercentSharesOut": 0.0076, "heldPercentInsiders": 0.00153, "heldPercentInstitutions": 0.84224, "shortRatio": 2.06, "shortPercentOfFloat": 0.0091, "impliedSharesOutstanding": 0, "bookValue": 11.831, "priceToBook": 31.266165, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1672444800, "earningsQuarterlyGrowth": 0.123, "netIncomeToCommon": 6244800000, "trailingEps": 6.9, "forwardEps": 11.71, "pegRatio": 1.94, "lastSplitFactor": "2:1", "lastSplitDate": 876960000, "enterpriseToRevenue": 12.34, "enterpriseToEbitda": 34.611, "52WeekChange": 0.26283622, "SandP52WeekChange": -0.06829989, "lastDividendValue": 1.13, "lastDividendDate": 1676332800, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "LLY", "underlyingSymbol": "LLY", "shortName": "Eli Lilly and Company", "longName": "Eli Lilly and Company", "firstTradeDateEpochUtc": 76253400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "7b37be39-dfde-3602-b0e4-4d76cf52143b", "messageBoardId": "finmb_285467", "gmtOffSetMilliseconds": -14400000, "currentPrice": 369.91, "targetHighPrice": 445.0, "targetLowPrice": 270.0, "targetMeanPrice": 383.29, "targetMedianPrice": 397.5, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 24, "totalCash": 2442299904, "totalCashPerShare": 2.713, "ebitda": 10175800320, "totalDebt": 17139399680, "quickRatio": 0.627, "currentRatio": 1.052, "totalRevenue": 28541399040, "debtToEquity": 159.06, "revenuePerShare": 31.652, "returnOnAssets": 0.110039994, "returnOnEquity": 0.62667, "grossProfits": 21911600000, "freeCashflow": 5488862720, "operatingCashflow": 7084400128, "earningsGrowth": 0.13, "revenueGrowth": -0.087, "grossMargins": 0.76771003, "ebitdaMargins": 0.35653, "operatingMargins": 0.30318, "financialCurrency": "USD", "trailingPegRatio": 1.7157}, "news": [{"uuid": "c0837ce6-8218-3daa-984d-615d6eeaba61", "title": "Nektar (NKTR) Starts New Restructuring Plan to Curb Cash Burn", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/nektar-nktr-starts-restructuring-plan-161404388.html", "providerPublishTime": 1681834444, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/IYksUEF.ZX5JOPFmQ194jQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["LLY", "NVO"]}, {"uuid": "f565b89d-9f20-3ba0-9e9f-d925e7e033bd", "title": "A Look At The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/look-intrinsic-value-eli-lilly-130019410.html", "providerPublishTime": 1681822819, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/bjOVive1cXtKhGvyLNQ92g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/1b6847ee48493a5698212be177362a15", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/_DzRXkvuY2vHQc4nbgEZgw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/1b6847ee48493a5698212be177362a15", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["LLY"]}, {"uuid": "9b4cdf32-003c-3d87-9f52-acdc69d5e56a", "title": "Demand for Obesity Drugs Has Insurers Paying Close Attention", "publisher": "The Wall Street Journal", "link": "https://finance.yahoo.com/m/9b4cdf32-003c-3d87-9f52-acdc69d5e56a/demand-for-obesity-drugs-has.html", "providerPublishTime": 1681760280, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/PV9sLNV9Kx_NAwZpG1qKqQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/cf4507a66d9805346892469e88d94ad2", "width": 1280, "height": 640, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/sqF1W1BipT93kiYVY7HUYQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/cf4507a66d9805346892469e88d94ad2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["LLY", "UNH", "ELV"]}, {"uuid": "9fc06eae-707e-3513-ba04-329f3c8950d9", "title": "SNY vs. LLY: Which Stock Is the Better Value Option?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/sny-vs-lly-stock-better-154003891.html", "providerPublishTime": 1681746003, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1", "width": 900, "height": 602, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/HGBb_w3iAqceoCyVMucmoA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["LLY", "SNY"]}, {"uuid": "79f2384a-abd9-345f-a3e9-aa2bad5b9f24", "title": "Eli Lilly to invest additional $1.6 billion in 2 new plants", "publisher": "Reuters", "link": "https://finance.yahoo.com/news/eli-lilly-invest-additional-1-153118515.html", "providerPublishTime": 1681745478, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/MOanGTWTIH8frYAvsDHUGQ--~B/aD01MzQ7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters-finance.com/7ee9345a66cda16d8cfd4489834e771c", "width": 800, "height": 534, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/jjRugOxzqug2IHj46MVHTg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/reuters-finance.com/7ee9345a66cda16d8cfd4489834e771c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["LLY"]}, {"uuid": "bc5afebc-a649-36f0-8cff-bd776ee7935d", "title": "UPDATE 1-Eli Lilly to invest additional $1.6 bln in 2 new plants", "publisher": "Reuters", "link": "https://finance.yahoo.com/news/1-eli-lilly-invest-additional-152610374.html", "providerPublishTime": 1681745170, "type": "STORY", "relatedTickers": ["LLY"]}, {"uuid": "19de643b-6f25-38b3-87b3-54017796d8b5", "title": "Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/lilly-record-breaking-investment-indiana-150000377.html", "providerPublishTime": 1681743600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/lVAuq1Sjy2.E_X33eK_R8A--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee", "width": 400, "height": 219, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/TASREDVp2ozZKc4y6JnrKw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["LLY"]}, {"uuid": "a3db0ba2-4203-3bfd-a61d-1bf9338d7181", "title": "The Zacks Analyst Blog Highlights Eli Lilly, Thermo Fisher Scientific, Lockheed Martin, Boston Scientific and Canadian Pacific Railway", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-eli-125312677.html", "providerPublishTime": 1681735992, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/qi8AmKRuXk4zL7mGsiR5yg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/arSYR7zbfSdn2ToJ5Ou4kQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["LMT", "LLY", "TMO", "BSX", "CP"]}]}